Abstract Library

#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide

Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Palazzo M, Catherine L, Guillaume C, Tamara M, Vinciane R,

Keywords: digestive endocrine tumors, lanreotide, tumor growth, Ki-67, liver metastases,

#103 From hormone dependent solid breast carcinoma to primary neuroendocrine carcinoma: a case report

Introduction: Primary neuroendocrine carcinoma of the breast is an extremely rare tumor with incidence of 0.27-0.5%.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Macut D, Kecman G, Bogavac T, Popovic B, Bozic I,

Keywords: neuroendocrine carcinoma, breast carcinoma, hormonal therapy,